New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2013
12:45 EDTIPI, COH, AET, PBI, MOS, AGU, MRK, OSK, HMA, POT, HLF, PFE, WU, CYHOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday as a report on rising home prices along with some better than expected earnings reports supported the market. The second quarter earnings season, which is reaching its peak this week, may not be turning out to be as bad as some had feared. However, the week's biggest events may still be yet to come, as investors brace for tomorrow's conclusion of the Fed’s two day FOMC meeting, along with the latest monthly jobs report, due Friday. ECONOMIC EVENTS: In the U.S., the S&P/Case-Shiller 20-city home-price index was up 12.2% from the prior year and was up about 1.0% from the prior month in May, which was close to in line with forecasts. The consumer confidence index for July fell to 80.3, which was a bit worse than the expectation for it to slip just slightly from its prior reading of 81.4. COMPANY NEWS: Several of the day's worst performing stocks were fertilizer companies after Russian potash producer Uralkali ended its cooperation with Belarus' Belaruskali. Following the news, Potash (POT) tumbled 20%, Mosaic (MOS) plunged 19%, Intrepid Potash (IPI) plummeted 30%, and Agrium (AGU) dropped nearly 5%... Among several notable healthcare names to announce quarterly results this morning, Pfizer (PFE) performed the best, rising almost 1% following its report. Its peer, Merck (MRK), slid about 1% after its own report, while health insurer Aetna (AET) was little changed in midday trade. MAJOR MOVERS: Among the notable gainers following their earnings reports were Oshkosh (OSK), up 12%, Pitney Bowes (PBI), up 11%, and Western Union (WU), up 9%. Shares of multi-level marketer Herbalife (HLF) also rose over 4% following its report in spite of new questions from Bill Ackman's Pershing Square, which has a very large and well documented short position in the stock. Among the noteworthy losers was upscale accessories maker Coach (COH), which fell more than 7% after the company reported mixed fourth quarter results, announced the departure of two senior executives, and agreed to sell its Reed Krakoff business. Also lower were shares of hospital chain Health Management Associates (HMA), which fell 11% after Community Health (CYH) agreed to buy the company for the equivalent of about $13.78 per share plus possible future considerations based on the outcome of certain legal matters. INDICES: Near noon, the Dow was up 10.37, or 0.07%, to 15,532.34; the Nasdaq was up 23.81, or 0.66%, to 3,622.95; and the S&P 500 was up 3.18, or 0.19%, to 1,688.51.
News For CYH;HMA;PBI;WU;OSK;AET;PFE;MRK;COH;HLF;AGU;IPI;POT;MOS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 13, 2015
17:19 EDTPFEPfizer, Merck KGaA to present data at ASCO for avelumab
Subscribe for More Information
13:43 EDTPFEHospira shareholders approve merger with Pfizer
Hospira (HSP) announced that Hospira shareholders voted in favor of the proposal to adopt the merger agreement with Pfizer (PFE) at a special meeting of stockholders held May 13 in Denver, Colorado. On February 5, Hospira and Pfizer announced they had entered into a merger agreement under which Pfizer will acquire Hospira for $90 per share in cash for a total enterprise value of approximately $17B. The merger is subject to customary closing conditions, one of which was approval of the merger by Hospira's shareholders. Additional closing conditions to be met include obtaining regulatory approvals in several jurisdictions. Hospira and Pfizer continue to expect the merger to close in the second half of 2015.
13:12 EDTMRKSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
10:18 EDTAETAnalyst says sell Humana amid 'wishful' takeover speculation
Subscribe for More Information
07:31 EDTPFEHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
May 12, 2015
18:47 EDTHLFCasino union requests Herbalife investigation, Reuters says
Subscribe for More Information
13:13 EDTMRKExpert says Norway biosimilar case an 'outlier,' CT Financial News reports
Subscribe for More Information
13:03 EDTAETAetna repeats view of FY15 operating EPS $7.20-$7.40, consensus $7.38
Subscribe for More Information
11:53 EDTAETAnalyst predicts large transaction 'imminent' for Aetna
Subscribe for More Information
10:04 EDTAETHigh option volume stocks
Subscribe for More Information
09:53 EDTAETAetna merger with Cigna or Humana likely 'imminent,' says Leerink
Subscribe for More Information
06:09 EDTMRKThreshold announces Merck receives FDA Fast Track designation for evofosfamide
Subscribe for More Information
May 11, 2015
17:36 EDTPFEAthersys down 10.1% after Pfizer notified that it will terminate agreement
Subscribe for More Information
17:34 EDTPFEAthersys receives notification that Pfizer will terminate agreement
Subscribe for More Information
16:33 EDTPFEPfizer takes minority interest in AM-Pharma, secures option to acquire company
AM-Pharma and Pfizer announced that Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company. The option becomes exercisable upon completion of a Phase II trial of recAP in the treatment of Acute Kidney Injury related to sepsis. There are no drugs currently approved for this condition and the only treatment option is dialysis and supportive care. Results from the current Phase II trial for recAP are expected in the second half of 2016. Under the terms of the agreement, Pfizer has made an upfront payment of $87.5M for the minority equity interest and exclusive option, with additional potential payments of up to $512.5M upon option exercise and potential launch of any product that may result from this agreement. Other terms of the transaction were not disclosed. “Pfizer is committed to advancing the science to address the high unmet medical need in Acute Kidney Injury,” said Mikael Dolsten, M.D., Ph.D., president, Worldwide Research and Development at Pfizer. “Clinical data for recAP show the potential to uniquely address Acute Kidney Injury in the setting of sepsis, and we look forward to working with our partners at AM-Pharma as we aim to accelerate the development of recAP into a potential first-in-class treatment for patients.”
15:06 EDTAETAetna backs FY15 operating EPS $7.20-$7.40, consensus $7.38
In a regulatory filing earlier, Aetna reported that during upcoming investor meetings in May, the company expects to reaffirm its FY15 operating EPS guidance of $7.20-$7.40. Current FY15 EPS consensus is $7.38.
08:45 EDTPBIPitney Bowes to sell marketing services organization to Red Ventures for $310M
Subscribe for More Information
08:11 EDTWUMacquarie to hold a conference
Subscribe for More Information
07:23 EDTAGUAgrium price target lowered to $126 from $138 at Susquehanna
Subscribe for More Information
06:51 EDTAETAetna management to meet with Leerink
Meeting to be held in Hartford, CT on May 11 hosted by Leerink.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use